Blood
Articles in this Issue
Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis
Abstract Background CD19-directed chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape for relapsed or...
Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion
Abstract Background: The Multiple Myeloma Research Foundation (MMRF) and its partners launched the MyDRUG platform clinical trial (NCT0373270...
Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial
Abstract Introduction: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphomas (TCL) are highly aggressive hematologic malignancies...
Peptide-based antagonists for targeting CXCR4 in ibrutinib resistant chronic lymphocytic leukemia
Abstract Bruton tyrosine kinase inhibitors (BTKi) have revolutionized chronic lymphocytic leukemia (CLL) treatment. However, resistance deve...
An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction
Abstract We are currently performing clinical studies (NCT05589896 and ossiumhealth.com/HOPE) with cryopreserved HPC, Marrow recovered from...
Mavs mediates inflammatory memory in hematopoietic stem cells and promotes ineffective hematopoiesis
Abstract Chronic inflammatory stress is a key characteristic of bone marrow failure syndromes (BMFS) and myelodysplastic syndromes (MDS), bu...
FOXP3 and helios expressing CD4+ T conventional cells are a regulatory-like subset that is induced after orca-T allogeneic immunotherapy
Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for many hematologic malignancies. The...
Why is diagnosing antiphospholipid syndrome so complex? characterization of cardiolipin chemical features required for antigenicity
Abstract Background: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in the pr...
Induction mortality in acute leukemia: The hidden burden of infections in a middle-income country
Abstract Background: Induction therapy is a critical phase in the treatment of acute leukemia (AL), yet mortality during this period remains...
Interplay between mutant DNMT3A and UBA1 worsens survival through altered inflammatory and metabolic pathways
Abstract Introduction: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is an adult-onset autoinflammatory disorder defined b...
A unified spatial & molecular atlas of anatomically restricted large B-cell lymphomas defines stereotyped cell ecosytems
Abstract Background Large B-cell lymphomas (LBCLs) are clinically and biologically heterogeneous, yet specific extranoda...
Droplet digital PCR outperforms conventional methods for early relapse prediction in AML/MDS patients post-transplant
Abstract Measurable residual disease (MRD) and donor chimerism (DC) monitoring are critical for early relapse prediction after allogeneic he...
SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes
Abstract SWOG 1318 evaluated the feasibility of combining the tyrosine kinase inhibitor (TKI) dasatinib with prednisone and blinatumomab in...
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Abstract Objective Bleximenib is a potent, selective menin inhibitor with activity in NPM1-mutated (NPM1m)or KMT2A-rearranged (KMT2Ar) acute...
An experiential learning intervention with community advisory boards to enhance clinical trial literacy in sickle cell disease: A baseline analysis
Abstract Background: Patient engagement is critical to the success of clinical trials. Community Advisory Boards (CABs)...
Clinician documentation and practices after declined medications for patients with sickle cell disease
Abstract Introduction Documentation in the electronic medical record (EMR) frequently includes the negative descriptor “refused”. Our prior...
Antiphospholipid syndrome (APS) is the newest member of the PF4 immunothrombotic family: Mechanistic and therapeutic insights
Abstract Background: APS is an autoimmune thromboinflammatory disorder characterized by venous, arterial, and microvascular thrombosis, adve...
Plasma proteomic analysis as a tool for monitoring the development of ibrutinib resistance in Waldenström macroglobulinemia.
Abstract About a decade ago, the BTK inhibitor ibrutinib (IBR) became the first approved agent for the treatment of patients with symptomati...
Mechanism of ruxolitinib is better in treating hydrxyurea resistan polycythemia vera (PV) than essential thrombicythemia (ET)
Abstract Introduction.Studies have shown that ruxolitinib is more effective in treating hydroxyurea-resistant PV than ET (Vannucchi et al.,...
Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)
Abstract Background Talquetamab (talq) is a GPRC5D-directed bispecific antibody (BsAb) approved for the treatment of relapsed and refractory...
Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
Abstract Background Allogeneic hematopoietic cell transplantation (HCT) is curative for myelofibrosis (MF), but relapse and graft-versus-hos...
Trial in progress: Galileo-3, a Phase 3 safety and efficacy trial of FLT201 gene therapy in patients with gaucher disease type 1
Abstract Background and Significance Gaucher disease (GD) is a rare genetic lysosomal storage disorder caused by variants in the GBA1 gene,...
High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study
Abstract Background Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas associated with poor survival outcome...
Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)
Abstract Introduction: IME, a first-in-class telomerase inhibitor, was approved in the US and EU for the treatment (tx) of certain adult pat...
Platelets modulate the CD4 T cell immune response during immune thrombocytopenia.
Abstract Introduction. The immunomodulatory functions of platelets in immune thrombocytopenia (ITP) have been scarcely investigated although...